U.S. Moves to Reschedule Cannabis Under Federal Law
Federal regulators initiate a process to move cannabis from Schedule I to Schedule III status.
Updated on Oct. 16, 2026 in Substance Abuse
Live Poll
Is moving cannabis to a lower federal restriction category a risk to public health?
In 2026, the federal government began a regulatory shift to reclassify cannabis from Schedule I to Schedule III. This change specifically targets FDA-approved products and those dispensed under state medical marijuana licenses.
Why it matters
The rescheduling effort aims to lower barriers to medical research and improve access for patients managing chronic pain, chemotherapy-induced nausea, or multiple sclerosis.
Clinical data indicates that 47.4% of patients diagnosed with cannabis-induced psychosis later received a diagnosis of schizophrenia or bipolar disorder. Research also suggests a recommended 6 to 8 hours of driving abstinence following inhalation.
The players
Drug Enforcement Administration
The federal agency is responsible for the oversight of the rescheduling regulatory actions.
Substance Abuse and Mental Health Services Administration
This agency conducts the National Survey on Drug Use and Health to track substance usage trends across the country.
The details
The Controlled Substances Act regulatory framework provides the mechanism for this reclassification, though the order excludes adult-use cannabis, bulk plant material, and synthetically derived THC. Pharmacists are tasked with monitoring the impact of these changes by assessing cytochrome P450 interactions and pharmacodynamic effects like sedation and anticholinergic activity.
Timeline
2025: SAMHSA National Survey on Drug Use and Health timeframe.
October 14, 2026: Access date for federal regulatory and research documents.
Health Landscape
This regulatory reclassification represents a formal adjustment to the scheduling hierarchy established by the Controlled Substances Act. By shifting cannabis, the government is updating its classification system to align with evolving scientific perspectives on medical utility.
The rescheduling could increase patient access to cannabis for specific medical conditions by simplifying research and distribution. Patients should consult healthcare providers regarding potential drug interactions, particularly those involving cytochrome P450 pathways.
The takeaway
The federal move to Schedule III highlights the balance between increasing therapeutic access and addressing the risks of cannabis use disorder. Individuals should be aware of psychiatric and cognitive risks identified in clinical data when considering cannabis for medical use.
Further reading
Find more information on Substance Abuse trends and current federal policy updates.
More information
Review the full details of the DEA marijuana rescheduling regulatory actions on the official portal.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Is moving cannabis to a lower federal restriction category a risk to public health?
